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Glanders is a highly contagious and often fatal zoonotic disease, primarily of solipds. In the developed world,
glanders has been eradicated. However, prior use of B. mallei as a biological weapon and its high mortality in
inhalation animal studies has affirmed B. mallei as a biodefense concern. This threat requires the development of
new glanders medical countermeasures (MCMs), as there is a lack of an effective vaccine and lengthy courses of
multiple antibiotics needed to eradicate B. mallei. Here, we present a literature review of human glanders in which
we discuss the clinical epidemiology and risk factors, potential routes of exposure, symptoms, the incubation
period, and specific diagnostics. This review focuses on pulmonary glanders, as this is the most likely outcome of a
biological weapons attack. Additionally, we outline current treatment regimens and propose a clinical definition of
human pulmonary glanders infection.
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Glanders is a highly contagious and often fatal zoonotic
disease primarily of solipeds such as horses, mules, and
donkeys. It was first described by the Greeks in 450–
425 BC and again by the Romans in 400–500 AD.
Throughout history glanders has been known by other
names including equinia, malleus, droes, and farcy [1-5].
Glanders is primarily characterized by ulcerating lesions
of the skin and mucous membranes. Solipeds are the nat-
ural reservoir of Burkholderia mallei. Donkeys are prone
to develop acute forms of glanders while horses are more
likely to develop chronic and latent diseases. Mules are
susceptible to acute and chronic forms of the disease as
well as latent infections [6-8]. B. mallei, the etiological
agent of glanders, is a Gram-negative, non-motile, facul-
tative intracellular pathogen. At one time, B. mallei infec-
tions occurred worldwide, but over the last 100 years the
occurrence of glanders has decreased with the reduced
economic reliance on solipeds as the primary mode of
transportation, the implementation of testing all solipeds
for glanders, and euthanizing those that are confirmed
positive. The last naturally occurring human case in the
United States was reported in 1934 [9]. Glanders in
solipeds and humans has also been eradicated from* Correspondence: cgelhaus@mriglobal.org
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distribution, and reproduction in any mediumCanada and Western Europe [10,11]. However, sporadic
infections of animals are still reported in Far East Asia,
South America, Eastern Europe, North Africa, and the
Middle East [12-14]. Although human epidemics have
not been recorded, isolated outbreaks in human popula-
tions and the deliberate use of B. mallei as a biological
weapon have been documented [15,16].
Although glanders has been eradicated from many
parts of the world, the threat of B. mallei being used as
a weapon is very real. In fact, B. mallei was one of the
first biological warfare agents used in the 20th century,
specifically during World War I [1]. These malicious at-
tacks on the opposing force’s animals were designed to
impair the movement of troops and artillery, ultimately
sabotaging a campaign. The former Soviet Union was
also alleged to have used weaponized B. mallei against
opposition forces in Afghanistan between 1982 and 1984
[2]. While the United States began work on biological
warfare agents in the 1940’s including B. mallei, it did
not weaponize B. mallei. However, during this work,
seven individuals working in the US labs became infected.
B. mallei has been considered a potential threat since the
1940’s because of its high infectivity, degree of incapacita-
tion, and agent availability [5]. As further evidence that
glanders is still considered a potential biological threat, thetral Ltd. This is an Open Access article distributed under the terms of the
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Enterprise convened subject matter experts at the 2010
HHS Burkholderia workshop in order to develop con-
sensus recommendations for post-exposure prophylaxis
against and treatment for B. mallei [17]. Glanders is rela-
tively unknown in the West and its clinical symptoms in
humans are nonspecific. Thus, diagnosis and treatment
may be delayed. Therefore, we have reviewed the glanders
literature to provide a description of human disease which
will assist researchers developing medical countermeasures
for glanders by creating a clinical definition against which
animal models of human glanders can be qualified.
Description of human glanders
Clinical epidemiology and risk factors
Zoonotic transmission of B. mallei from solipeds to
humans appears to be uncommon, even in cases of fre-
quent and close contact with infected animals. However,
rigorous examination regarding the rarity of transmis-
sion has not been conducted. Hypotheses to explain this
low incidence include low organism concentrations at the
infection sites or a high infectious dose required to cause
disease in humans [9]. Despite the low incidence of animal
to human transmission occupational exposure remains a
key risk factor among veterinarians, veterinary students,
farriers (hoof care workers), flayers (hide workers), trans-
port workers, soldiers, slaughterhouse personnel, farmers,
horse fanciers, and stable hands [9]. Subclinical infections
in horses and mules also pose a hidden risk to humans, al-
beit a low risk. While infection by ingesting contaminated
food and water has occurred, it does not appear to be a sig-
nificant route of entry for human infections [18-20].
Human-to-human transmission is also rare. However,
it may occur during occupational exposure in medical
practice or at autopsies [3,9,19,21]. Transmission has also
occurred in home settings, where the care of glanders-
infected individuals has led to the infection of other fam-
ily members [21].
While laboratory workers have rarely been infected,
their close contact with high concentrations of virulent
organism puts them at a higher risk for infection. Eight
cases of laboratory acquired glanders have been reported
between 1943 and the present at US research centers, spe-
cifically Fort Detrick, Maryland. Seven of the eight Fort
Detrick laboratory-acquired infections occurred prior to
modern biological containment practices [22]. The first six
cases occurred during the performance of normal labora-
tory procedures that could generate aerosols such as wash-
ing, centrifugation, and aerating B. mallei cultures. In
contrast to zoonotic transmission, aerosols of B. mallei are
highly infectious [22]. Unfortunately, the seventh case is
not well described in published literature. The eighth case
may have resulted from inconsistent use of personal pro-
tective equipment particularly latex gloves [3,9,23].Routes of infection
Glanders is transmitted by direct invasion of abraded or
lacerated skin; inhalation with deep lung deposition; and
by bacterial invasion of the nasal, oral, and conjunctival
mucous membranes. The occupational exposures de-
scribed above most often occur through exposed skin,
particularly the hands, arms, neck, and face [9]. B. mallei
is not believed to penetrate normal intact skin, although
wounds or penetrations during the likely exposure inter-
val were not identified in many cases [9]. Indeed, most
laboratory-acquired infections are not associated with in-
jury or a recollection of injury [24]. In the case of the
eighth case mentioned above, a break in the skin or a
specific exposure-associated laboratory incident (needle
stick or broken glassware) was not recalled or identified.
However, this patient reported collecting a personal
blood sample via a finger-stick for diabetic monitoring
prior to entering the laboratory [9]. In light of the lack of
glove use, the finger-stick site may have been the poten-
tial entry point of the bacteria. The clinical manifestation
of unilateral axillary lymphadenopathy in this patient was
consistent with percutaneous infection.
Six of the eight cases above were described in Howe and
Miller’s report which detailed glanders cases occurring
within one year among Fort Detrick laboratory personnel
working with B. mallei (referred to as Malleomyces mallei
in the report), including two notable cases [22]. Two
workers (patients one and two) were present when a flask
containing B. mallei was dropped and broken thus poten-
tially creating aerosol droplets. Both patients were admitted
to the hospital on the same day, approximately two weeks
after the incident and were the only personnel present in
the lab when the flask was dropped. The other four pa-
tients (patients three to six) were actively engaged in wash-
ing B. mallei growth from agar plates for the preparation
of vaccines approximately 10–14 days prior to the on-
set of their symptoms. While all workers wore the required
protective clothing at the time and used caution while
performing their duties, the possibility that they inhaled an
aerosol could not be eliminated. Patient four also failed to
heat kill the B. mallei sample they were working with prior
to making dilutions for turbidity measurements two weeks
before symptom onset. Approximately two weeks before
their admission to the hospital, patients five and six had
engaged in procedures involving the aeration of cultures.
They recalled that on at least two occasions, the containers
had been opened immediately after the air current had
been turned off, rather than after a period of delay long
enough to avoid the escape of aerosolized organisms into
the room. Additionally, these two patients were working
with a strain of organism of higher virulence than the other
four. These events strongly suggest aerosol route of infec-
tion by B. mallei can result in human glanders cases, espe-
cially in the laboratory setting [22].
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The acute form of disease has a typical incubation
period of 1–14 days [25], while the chronic form of the
disease has an incubation period of up to 12 weeks. A
localized infection typically follows within one to five
days of exposure and may be characterized by swelling
of the affected area and a weeping discharge. Acute pul-
monary infections may require anywhere from 10–14 days
of incubation before symptoms appear [25]. Septicemia
may develop immediately after exposure or up to two
weeks after initial infection. Pneumonic disease usually has
a rapid onset and is almost uniformly lethal between 10
and 30 days in untreated cases [22]. Figure 1 summarizes
the time between exposure and symptoms. An important
feature of the eight cases that have occurred since 1943 is
that at least half of the patients not only felt better but also
experienced improved clinical signs for a period of time
after the first wave of symptoms and prior to a second
wave of symptoms. This period of temporary improvement
has the potential to be misinterpreted as eradication of dis-
ease by patient and physician. Such temporary improve-
ment should not limit recommended treatments.
Diagnostics
The definitive diagnosis of glanders requires isolation of
the organism and positive identification. Radiology may
reveal abcesses in multiple organs including lungs, liver,
and spleen, but these abcesses are indistinguishable from
those caused by other disease and specific diagnosis is
required [26]. While there is no validated in vitro diag-
nostic test for glanders, experimental serological tests,
such as agglutination and complement fixation tests
[27-29], and PCR based tests [30] have been used on a
limited and experimental basis in solipeds as an alternative
to isolating the organism. An indirect hemagglutinationTime to Onset o
Exposure
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Figure 1 Time from exposure to symptoms.assay (IHA) used to diagnose melioidosis in endemic re-
gions can also be used to diagnosis glanders [31]. Briefly,
the IHA uses Burkholderia antigens to coat sheep red
blood cells prior to their incubation with serum from
suspected melioidosis (or glanders) patients. In the re-
sulting reaction the antigen-coated sheep RBCs agglu-
tinate or form a pellet if the patient is seropositive for
B. pseudomallei or B. mallei (i.e., possesses antibodies
to these pathogens) [31,32]. Since antibodies from glan-
ders and melioidosis patients cross react with antigens
present on a variety of Burkholderia species, the IHA
assay is not a specific diagnostic test and other glanders-
specific diagnostic tests are needed [31,33]. The mallein
test is used for veterinary diagnostic purposes and in-
volves injecting purified protein derivatives intradermally
to observe a delayed type hypersensitivity reaction, simi-
lar to the tuberculin test for tuberculosis [34]. However,
this test is not used in human diagnostics.
Features of human clinical glanders
General symptoms
Many forms of glanders have been described, including
chronic, disseminated, pulmonary, and septicemic. The
variety of infections is largely explained by various routes
of infection. Localized infections are generally regionally
confined and typically characterized by foci of suppuration.
The abscesses can ulcerate and drain for long periods of
time. However, localized infections may disseminate, lead-
ing to pulmonary, septicemic, or multi-tissue infection [9].
The most common clinical features of the eight laboratory-
acquired infections from Fort Detrick included (in order of
most common occurrence) afternoon to evening low-grade
fever, malaise, fatigue, headache, myalgias including back-
ache, lymphadenopathy, and chest pain. Approximately
half of the patients not only felt better but were alsof Infection
lmonary Infection
monic Disease
Onset of Chronic Disease
Table 1 Antibiotics to which B. mallei is commonly
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of disease symptoms. This period lasted from a few
days to 2 months then patients developed clinical signs
of infection.
Mucosal involvement
Involvement of the eye and conjunctiva in a B. mallei in-
fection presents with excessive lacrimation and photopho-
bia. Nasal involvement is characterized by inflammation
and swelling of the nose, which is common following in-
halation of B. mallei. This may be followed by copious
nasal discharge. Additionally, infection may invade the
nasal septum and bony tissues, causing fistulae and tissue
destruction [9]. The face may swell and regional lymph
nodes may become inflamed. Infection may also extend
lower in the respiratory tract, resulting in bronchitis which
can be accompanied by cough and mucopurulent sputum
production. Constitutional signs and symptoms such as
fever and chills typically occur within the first few days fol-
lowing infection. Additionally, these symptoms may persist
through treatment and be severe. Common signs and
symptoms can include, but are not limited to, fever or low-
grade fever in the afternoon to evening; chills with or with-
out rigors; and severe headache [9].
Cutaneous involvement
Cutaneous manifestations include papular lesions that
may erupt anywhere on the body with a more chronic,
indolent course of infection. B. mallei entry through an
abrasion is typically followed by an inflammatory response,
including pain and swelling. In these cases, a glanders node
may appear as a single blister, gradually developing into
an ulcer that may become hemorrhagic [18,35]. A local-
ized infection with a discharge typically develops at the
entry site. Inflammation may extend along regional lym-
phatics and cause lymphangitis with numerous foci of
suppuration along their course. The endotoxins present
in B. mallei strains affect the smooth muscle of the lym-
phatics [9] by enhancing the irritation and inflammation
seen in the lymphatics.
Pulmonary involvement
A pulmonary infection typically results in pneumonia,
pulmonary abscess, pleuritis, and plural effusion. Signs and
symptoms of pulmonary infection can include cough, dys-
pnea, chest pain, and mucoplurent sputum. Nonspecific
signs and symptoms such as fatigue, fever (often exceeding
102°F), chills, headache, myalgias, lymphangitis, sore
throat, pleuritic chest pain, cough, tachypnea, dyspnea,
discharge, and gastrointestinal signs often accompany re-
spiratory infections [9]. Many symptoms may take up to
2 to 3 weeks to develop. Nonspecific signs, such as dizzi-
ness, rigors, myalgia, nausea, night sweats, severe head-
ache, tachycardia, weight loss, and mucosal eruptions arealso usually present and may indicate a disseminated
infection [9].
Dissemination of infection
Dissemination from local cutaneous or mucosal infec-
tion result in septicemia and the colonization of internal
organs such as the spleen, liver, and lungs with the de-
velopment of abscesses [9]. Ultrasonography and com-
puted tomography may reveal multiple, small discrete
abscesses in both the liver and the kidney [23]. These in-
fections are typically associated with septic shock and
high mortality.
Treatment of human glanders
Because of the rarity of human glanders cases, limited
information exists regarding the use of antibiotics for
the treatment of infected humans. However, B. mallei
infections have responded to antibiotic therapy despite
slow recovery times after delayed diagnosis or disseminated
disease. B. mallei has been reported to be susceptible to
many antibiotics in vitro [36-43]. Because B. mallei is a fac-
ultative intracellular pathogen, aminoglycosides and other
antibiotics that are incapable of penetrating host cells are
most likely not useful for the treatment of infection
[40,41,43]. Most B. mallei strains exhibit resistance to sev-
eral antibiotics (Table 1), due in part to the exclusion of an-
tibiotics from host cells [3,9,15,18].
Antibiotic efficacy has been tested against glanders in
solipeds, hamsters, guinea pigs, and monkeys [38,42,43,
45-47]. In hamsters, sodium sulfadiazine effectively treated
acute glanders while penicillin and streptomycin were not
effective [42]. Additionally, doxycycline and ciprofloxacin
have been tested as post-exposure therapeutics in hamsters
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[43]. This study demonstrated that doxycycline therapy
is superior to ciprofloxacin therapy when administered
up to 48 hours after infection. It should be noted that
some of these hamsters had a relapse of symptoms two
to three weeks after discontinuation of ciprofloxacin
treatment and four to five weeks after discontinuation of
doxycycline treatment [43]. Additionally, doxycycline was
able to provide 70% protection to hamsters following a
low dose (5 × 102 CFUs or 16 LD50s) aerosol challenge
[9,45]. All tested antibiotics were ineffective against a
high dose (5 × 103 CFUs or 160 LD50s) of B. mallei deliv-
ered by aerosol [45].
The majority of human glanders cases occurred before
antibiotic treatment was available, and over 90% of infected
people succumbed to disease [48]. Of the human glanders
cases recorded since the 1940s, several have been treated
successfully with antibiotics [9,22,23,49,50]. Sulfadiazine
was used to successfully treat six of the previously
discussed laboratory-acquired infections at Fort Detrick,
as well as two additional cases of non-laboratory acquired
glanders described in 1951 [22,49]. The seventh case
was successfully treated with a tetracycline derivative,
aureomycin. In the most recent case of laboratory-acquired
glanders, the patient initially received a 10-day course of a
first-generation cephalosporin but symptoms persisted for
a few weeks. The patient then received a 10-day course of
clarithromycin, but symptoms returned 4 days after treat-
ment was stopped. The patient was then successfully
treated with imipenem and doxycycline intravenously for
1 month followed by oral azithromycin and doxycycline for
6 months [9,23].
Given the lack of historical data, current treatment regi-
mens for human glanders are not well understood at this
point in time, and no FDA approved treatment or treat-
ment regimen exists. An exhaustive review of current and
experimental treatments for both glanders and melioidosis
has been published, but this review also describes the lack
of clinical information for glanders treatment [51]. How-
ever, in order to manage laboratory exposures, treatment
recommendations have been made [52]. Symptomatic case
treatment of glanders requires a concurrent two pronged
approach consisting of both an intensive intravenous (IV)
therapy and oral eradication therapy. IV medication op-
tions are imipenem, meropenem or ceftazidime with or
without trimethoprim-sulfamethoxazole (TMP-SMX). IV
dosing schedule should last a minimum of 10 days andTable 2 Treatment recommendations
Intensive IV therapy
Imipenem 25 mg/kg up to 1 g every six hours T
Meropenem 25 mg/kg up to 1 g every eight hours
Ceftazidime 50 mg/kg up to 2 g every six hours Amoxicillin-cmay be longer depending on the severity of illness. Oral
therapy timing is also dependent on the severity of the dis-
ease and may run 12 weeks to as long as 12 months in dur-
ation. The treatment of choice for oral antibiotic therapy
options are TMP-SMX as noted above with or without
a secondary oral medication of doxycycline. Alternate
therapies for TMP-SMX resistant B. mallei or patient
intolerance consist of doxycycline, macrolides, chloram-
phenicol, quinolones, or amoxicillin-clavulanate as noted
in the Occupational Health Manual from the United States
Army Medical Research Institute of Infectious Diseases
(USAMRIID) [52]. Since B. mallei and B. pseudomallei are
similar, it is postulated that drug therapy experiences
should be similar as well. Thus, doxycycline, amoxicillin-
clavulante and quinolones monotherapies are at a greater
risk of relapse than TMP-SMX and chloramphenicol.
Dosing regimen recommendations are shown in Table 2.
Disease outcomes in humans
The mortality rate for the pulmonary form of glanders
has been reported to be 90-95% without treatment and
up to 40% with treatment. The reported mortality rate
for the septicemic form of glanders is greater than 95%
without treatment and as high as 50% with treatment.
The mortality rate for the untreated cutaneous form of
glanders is 90-95% if it becomes systemic and as high as
50% with treatment. In the case of chronic glanders, the
mortality rate may be as high as 50% despite treatment
[53]. It should be noted that the previously reported
mortality rates are likely to be extrapolations from the
related disease melioidosis and that lack of recent hu-
man cases makes determining mortality difficult. A brief
period of apparent recovery is a common clinical feature
that can easily lead to delayed treatment and complica-
tions. However, despite the fact that three of the eight
U.S. laboratory patients experienced a two month delay
in effective treatment they were all successfully cured.
These high success rates may reflect the quality of sup-
portive care each patient received and the availability of
appropriate antibiotics. The most recent patient had dis-
seminated disease, and required ventilator assistance as
well as a prolonged course of multiple antibiotics before
improving. This patient was treated with imipenem and
doxycycline, and there was rapid improvement. After two
weeks, the imipenem was replaced by azithromycin, and
the patient completed a six-month course of treatment
with azithromycin and doxycycline [9,23]. In order toOral eradication therapy
MP-SMX 8/40 mg/kg up to 320 mg/1600 mg every 12 hours
Doxycycline 2.5 mg/kg up to 100 mg every 12 hours
lavulanate 500 mg every eight hours or 875 mg every 12 hours for adults
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casualty situation, well-controlled animal studies con-
ducted under the FDA animal rule would provide scientific
evidence to efficiently direct medical treatment.
Clinical definition of human pulmonary glanders
The following first two criteria and at least one of last
two criteria are proposed for diagnostic confirmation of
acute pulmonary glanders infection in humans.
1. Development of constitutional symptoms such as
fever, rigors, myalgias, fatigue, headache, severe
malaise, and pleuritic chest pain [22].
2. Chest X-Ray exhibiting new onset of infiltrates
either segmental or lobar which may appear as
nodular opacities. May also exhibit cavitary lesions
or abscesses not only in the lungs but virtually any
remote sites such as spleen, liver, subcutaneous
tissue and muscle.
3. Positive isolation of B. mallei organism from sites
such as cavitary lesions or abscesses not only in the
lungs but virtually any remote site such as spleen,
liver, subcutaneous tissue, and muscle as well as
secretions, sputum, blood, and urine [52].
4. Positive Burkholderia species non-specific IHA
titer and if positive a follow-up four-fold titer
increase [52,54].
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